Literature DB >> 26280816

Fractional laser-assisted drug delivery: Active filling of laser channels with pressure and vacuum alteration.

Andrés M Erlendsson1,2, Apostolos G Doukas1, William A Farinelli1, Brijesh Bhayana1, R Rox Anderson1, Merete Haedersdal1,2.   

Abstract

BACKGROUND AND
OBJECTIVE: Ablative fractional laser (AFXL) is rapidly evolving as one of the foremost techniques for cutaneous drug delivery. While AFXL has effectively improved topical drug-induced clearance rates of actinic keratosis, treatment of basal cell carcinomas (BCCs) has been challenging, potentially due to insufficient drug uptake in deeper skin layers. This study sought to investigate a standardized method to actively fill laser-generated channels by altering pressure, vacuum, and pressure (PVP), enquiring its effect on (i) relative filling of individual laser channels; (ii) cutaneous deposition and delivery kinetics; (iii) biodistribution and diffusion pattern, estimated by mathematical simulation.
METHODS: Franz diffusion chambers (FCs) were used to evaluate the PVP-technique, comparing passive (AFXL) and active (AFXL + PVP) channel filling. A fractional CO2-laser generated superficial (225 µm;17.5 mJ/channel) and deep (1200 µm; 130.5 mJ/channel) channels, and PVP was delivered as a 3-minutes cycle of 1 minute pressure (+1.0 atm), 1 minute vacuum (-1.0 atm), and 1 minute pressure (+1.0 atm). Filling of laser channels was visualized with a colored biomarker liquid (n = 12 FCs, n = 588 channels). Nuclear magnetic resonance quantified intracutaneous deposition of topically applied polyethylene glycol (PEG400) over time (10 minutes, 1 hour, and 4 hours), investigated with (n = 36 FCs) and without (n = 30 FCs) PVP-filling. Two-dimensional mathematical simulation was used to simulate intradermal biodistribution and diffusion at a depth of 1,000 µm.
RESULTS: Active filling with application of PVP increased the number of filled laser channels. At a depth of 1,000 µm, filling increased from 44% (AFXL) to 94% with one PVP cycle (AFXL + PVP; P < 0.01). Active filling greatly enhanced intracutaneous deposition of PEG400, resulting in a rapid delivery six-folding uptake at 10 minutes (AFXL 54 µg/ml vs. AFXL + PVP 303 µg/ml, P < 0.01). AFXL alone generated an inhomogeneous uptake of PEG400, which greatly improved with active filling, resulting in a uniform uptake within the entire tissue.
CONCLUSION: Active filling with PVP secures filling of laser channels and induces a deeper, greater, more rapid delivery than conventional AFXL. This delivery technique has promise to improve treatment efficacy for medical treatments of dermally invasive lesions, such as BCCs.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  active filling; drug delivery; laser; laser-assisted drug delivery

Mesh:

Substances:

Year:  2015        PMID: 26280816     DOI: 10.1002/lsm.22374

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  4 in total

1.  Sustained epidermal powder drug delivery via skin microchannels.

Authors:  Yan Cao; Prateek Kakar; Md Nazir Hossen; Mei X Wu; Xinyuan Chen
Journal:  J Control Release       Date:  2017-01-27       Impact factor: 9.776

Review 2.  Update of Ablative Fractionated Lasers to Enhance Cutaneous Topical Drug Delivery.

Authors:  Jill S Waibel; Ashley Rudnick; Deborah R Shagalov; Danielle M Nicolazzo
Journal:  Adv Ther       Date:  2017-07-07       Impact factor: 3.845

3.  Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin.

Authors:  Emily Wenande; Uffe H Olesen; Malene R Boesen; Daniel P Persson; Catharina M Lerche; Stefan Stürup; Bente Gammelgaard; Søren Husted; R Rox Anderson; Merete Haedersdal
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

4.  Drug penetration enhancement techniques in ablative fractional laser assisted cutaneous delivery of indocyanine green.

Authors:  Arne A Meesters; Marilin J Nieboer; Mitra Almasian; Giota Georgiou; Menno A de Rie; Rudolf M Verdaasdonk; Albert Wolkerstorfer
Journal:  Lasers Surg Med       Date:  2019-03-25       Impact factor: 4.025

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.